Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer

Weekly docetaxel combined with irinotecan has acceptable safety and modest efficacy in the second-line treatment of advanced oesophagogastric cancer. Further prospective evaluation of this regimen is warranted.